BIOMAT Database Logo BIOMAT Database Logo

The novel metabotropic glutamate receptor agonist 2R,4R-APDC potentiates stimulation of phosphoinositide hydrolysis in the rat hippocampus by 3,5-dihydroxyphenylglycine: evidence for a synergistic interaction between group 1 and group 2 receptors. 1996

D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.

The mGlu receptor subtypes and second messenger pathways that mediate 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) responses in brain tissues are not fully understood. 1S,3R-ACPD differs from 3,5-dihydroxyphenylglycine (DHPG) or quisqualate in that 1S,3R-ACPD also activates group 2 mGlu receptors (mGlu2 and mGlu3) that are negatively linked to cAMP formation. To investigate the contribution of group 2 mGlu receptor activity of 1S,3R-ACPD to the phosphoinositide response in the rat hippocampus, we examined the effects of the novel group 2 mGlu receptor agonist 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC). 2R,4R-APDC did not activate or inhibit group 1 mGlu receptors (human mGlu1 alpha and mGlu5a) or group 3 mGlu receptors (human mGlu4 and mGlu7), but potently decreased forskolin-stimulated cAMP formation in human mGlu2- and mGlu3-expressing cells. In slices of the adult rat hippocampus 2R,4R-APDC had no effect on basal phosphoinositide hydrolysis; however, it was found to greatly enhance phosphoinositide hydrolysis to DHPG or quisqualate. In the neonatal rat hippocampus, 2R,4R-APDC enhanced the potency of DHPG, while not affecting the maximal response to group 1 mGlu receptor agonists. Thus, the phosphoinositide response in the rat hippocampus to 1S,3R-ACPD is mediated by a synergistic interaction between group 1 and group 2 mGlu receptors.

UI MeSH Term Description Entries
D007294 Inositol An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction. Myoinositol,Chiro-Inositol,Mesoinositol,Chiro Inositol
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010716 Phosphatidylinositols Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to the hexahydroxy alcohol, myo-inositol. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid, myo-inositol, and 2 moles of fatty acids. Inositide Phospholipid,Inositol Phosphoglyceride,Inositol Phosphoglycerides,Inositol Phospholipid,Phosphoinositide,Phosphoinositides,PtdIns,Inositide Phospholipids,Inositol Phospholipids,Phosphatidyl Inositol,Phosphatidylinositol,Inositol, Phosphatidyl,Phosphoglyceride, Inositol,Phosphoglycerides, Inositol,Phospholipid, Inositide,Phospholipid, Inositol,Phospholipids, Inositide,Phospholipids, Inositol
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012118 Resorcinols A water-soluble crystalline benzene-1,3-diol (resorcinol) and its derivatives. m-Dihydroxybenzenes,meta-Dihydroxybenzenes,m Dihydroxybenzenes,meta Dihydroxybenzenes
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D003515 Cycloleucine An amino acid formed by cyclization of leucine. It has cytostatic, immunosuppressive and antineoplastic activities. 1-Aminocyclopentanecarboxylic Acid,Aminocyclopentanecarboxylic Acid,NSC 1026,1 Aminocyclopentanecarboxylic Acid,Acid, 1-Aminocyclopentanecarboxylic,Acid, Aminocyclopentanecarboxylic
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug

Related Publications

D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
2R,4R-APDC, a Metabotropic Glutamate Receptor Agonist, Reduced Neuronal Apoptosis by Upregulating MicroRNA-128 in a Rat Model After Seizures.
March 2018, Neurochemical research,
D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
The group I metabotropic glutamate receptor agonist (S)-3,5-dihydroxyphenylglycine induces a novel form of depotentiation in the CA1 region of the hippocampus.
October 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience,
D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
Seizures and neuronal damage induced in the rat by activation of group I metabotropic glutamate receptors with their selective agonist 3,5-dihydroxyphenylglycine.
February 1998, Journal of neuroscience research,
D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
Effect of the group II metabotropic glutamate agonist, 2R,4R-APDC, varies with age, layer, and visual experience in the visual cortex.
July 1999, Journal of neurophysiology,
D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
1-amino-APDC, a partial agonist of group II metabotropic glutamate receptors with neuroprotective properties.
June 1999, Bioorganic & medicinal chemistry letters,
D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
Group I metabotropic glutamate receptor agonist causes neurodegeneration in rat hippocampus.
January 1997, Journal fur Hirnforschung,
D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
Effects of quisqualic acid analogs on metabotropic glutamate receptors coupled to phosphoinositide hydrolysis in rat hippocampus.
August 1995, Neuropharmacology,
D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists.
March 1999, Brain research,
D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740.
April 1997, Neuroreport,
D D Schoepp, and C R Salhoff, and R A Wright, and B G Johnson, and J P Burnett, and N G Mayne, and R Belagaje, and S Wu, and J A Monn
3,5-Dihydroxyphenyl-glycine: a potent agonist of metabotropic glutamate receptors.
November 1992, Neuroreport,
Copied contents to your clipboard!